February 28, 2017 12:49 AM ET

Pharmaceuticals

Company Overview of Cempra, Inc.

Company Overview

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta, an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative r...

6320 Quadrangle Drive

Suite 360

Chapel Hill, NC 27517

United States

Founded in 2005

93 Employees

Phone:

919-313-6601

Key Executives for Cempra, Inc.

President and Chief Commercial Officer
Age: 42
Total Annual Compensation: $330.0K
Founder and Scientific Consultant
Age: 67
Total Annual Compensation: $510.0K
Chief Financial Officer and Executive Vice President
Age: 53
Total Annual Compensation: $350.0K
Chief Medical Officer
Age: 58
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2015.

Cempra, Inc. Key Developments

Cempra, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-15-2017 10:00 AM

Cempra, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-15-2017 10:00 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States.

Cempra, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-11-2017 03:30 PM

Cempra, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-11-2017 03:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: David S. Moore, President and Chief Commercial Officer.

Cempra, Inc. - Special Call

To discuss on the Complete Response Letter (CRL) of the U.S. Food and Drug Administration (FDA) relating to the company’s new drug applications (NDAs) for oral and intravenous solithromycin for the treatment of community-acquired bacterial pneumonia (CABP) in adults

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cempra, Inc., please visit www.cempra.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.